East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, ‘Cambrex”) announced that Cambrex Karlskoga’s new $20 million cGMP manufacturing facility, which took 2 years to build, was officially opened on March 6th.
“We are very proud of our project team as they finished the project on time and within budget. We are pleased to offer our pharmaceutical customers a best-in-class cGMP plant,” says Ulf Nordzell, Managing Director for Cambrex Karlskoga.
Cambrex Karlskoga produces active pharmaceutical ingredients. During the last ten years, the company has continued to support innovative pharmaceutical companies with their drug development programs.
“To support our pharmaceutical industry focus, we completed a new kilo laboratory and invested in our pilot plants. This is the first full-scale cGMP plant we have built since we started our current business focus,” says Ulf Nordzell.
The new plant gives Cambrex Karlskoga a new flexible production plant, which will increase large-scale production capacity for new active pharmaceutical ingredients and the design has incorporated state-of-the-art cGMP, environmental and safety features.